Information Provided By:
Fly News Breaks for July 21, 2015
HSTM
Jul 21, 2015 | 07:51 EDT
Canaccord believes Healthstream's Q2 results were impressive and should be viewed positively while its maintained guidance will ultimately prove to be conservative. The firm noted annual revenue per subscriber increased sequentially, which they said supports the foundation for their view. Canaccord reiterated its Buy rating and $37 price target on Healthstream shares.
News For HSTM From the Last 2 Days
There are no results for your query HSTM